Vaccinia Inhibition of gd T cells is a Immune Evasion Mechanism

痘苗病毒对 gd T 细胞的抑制是一种免疫逃避机制

基本信息

  • 批准号:
    7500233
  • 负责人:
  • 金额:
    $ 17.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-09-30 至 2009-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Gammadelta T cells use an alternative receptor for MHCunrestricted recognition and are found in all lymphoid compartments of the human body. The gammadelta (gd) cells recognize cells infected by virus or intracellular bacteria, tumor cells and small molecule antigens. A major question is: Are gd T cells are required for protection against human viral diseases? Previous studies including our own work on HIV disease, provided correlative data for a gd T cell role in viral disease but there are no compelling studies in human or nonhuman primate systems and mechanisms of action have not been defined. Using the model of vaccinia infection, we will determine whether gd T cells are required and define their contributions to protective immunity. Vaccinia is a naturally attenuated vaccine against smallpox in man. The gd T cells are essential for vaccinia immunity in the mouse, where they provide T cell help in the absence of CD4+ cells and promote IgM to IgG isotype switching with the development of neutralizing antibodies although similar functions for g T cells have not been studied in primate species. Our own work revealed a potent, vaccinia-mediated inhibition of human gd T cells. Immune evasion mechanisms generally indicate that the target cells (here gd T cells) are part of the protective response. Studies in this proposal seek to define the mechanism for vaccinia-mediated inhibition of human gd T cells, to test cytokines and TLR agonists for the ability to reverse inhibition, and to perform pilot studies in nonhuman primates for testing the role of gd T cells in the development of vaccinia immunity. Work in this proposal, representing efforts of the Pauza group, the Hoft laboratory in St. Louis University, Bernie Moss at the NIH/NIAID and Yiming Shao from the China CDC, are highly significant for advancing our understanding of gd T cells, for evaluating novel therapeutic approaches to viral disease, for improving vaccine efficacy by stimulating gd T cells, and for efforts to generate safer and more immunogenic vaccinia as smallpox vaccines or as viral vectors. The major human gd T cell subset can be activated in vivo with existing clinical drugs, a direction being tested in novel therapies for cancer, and similar approaches may be useful for viral diseases and vaccination. A subset of human lymphocytes called gammadelta (gd) T cells, are postulated to be important for protective immunity against viral diseases but existing studies provide correlations with disease and have not proven the requirement or defined a mechanism of action for their contribution. Recently, we showed that vaccinia virus (the naturally occurring vaccine against smallpox) potently inhibits gd T cells, suggesting they are part of the mechanism that controls vaccinia infection in man. Our goals are to test the hypothesis that gd T cells are necessary for viral immunity and to pursue the development of new therapies and improved vaccination approaches that incorporate direct stimulation of gd T cells.
描述(由申请人提供):γ δ T细胞使用MHC的替代受体,不受限制 识别,并发现在人体的所有淋巴隔室。的 γ δ(GD)细胞识别被病毒或细胞内细菌感染的细胞、肿瘤细胞和小 分子抗原。一个主要的问题是:gd T细胞是保护人类免受病毒感染所必需的吗? 疾病?以前的研究,包括我们自己对HIV疾病的研究,为gd T提供了相关数据。 细胞在病毒疾病中的作用,但在人类或非人类灵长类动物系统中还没有令人信服的研究 作用机制尚未确定。使用牛痘感染模型,我们将 确定是否需要gd T细胞并定义它们对保护性免疫的贡献。 牛痘是一种天然减毒的人类天花疫苗。 在小鼠中的牛痘免疫,其中它们在缺乏CD4+细胞的情况下提供T细胞帮助, 促进IgM向IgG同种型转换,并产生中和抗体,尽管与 尚未在灵长类物种中研究gT细胞的功能。我们自己的工作揭示了一种强大的, 牛痘介导的对人gd T细胞的抑制。免疫逃避机制通常表明, 靶细胞(此处为gd T细胞)是保护性应答的一部分。本建议中的研究旨在 明确牛痘介导的人gd T细胞抑制机制,检测细胞因子和TLR 激动剂逆转抑制的能力,并在非人灵长类动物中进行试点研究, 测试gd T细胞在牛痘免疫发展中的作用。在这个提案中, 代表Pauza小组的努力,圣路易斯大学的Hoft实验室, NIH/NIAID和中国疾控中心的Yiming Shao,对于推进我们的研究具有重要意义。 对gd T细胞的了解,用于评估病毒性疾病的新治疗方法,用于改善 通过刺激gd T细胞来提高疫苗效力,并努力产生更安全和更具免疫原性的疫苗。 牛痘作为天花疫苗或作为病毒载体。主要的人gd T细胞亚群可以在 体内与现有的临床药物,一个方向正在测试的新疗法的癌症,和类似的 这些方法可用于病毒性疾病和疫苗接种。人类淋巴细胞的一个亚群, γ δ(gd)T细胞被认为对于抵抗病毒性疾病的保护性免疫是重要的 但现有的研究提供了与疾病的相关性,但尚未证明这一要求或定义 其贡献的作用机制。最近,我们发现,牛痘病毒(自然 天花疫苗)有效地抑制gd T细胞,表明它们是天花疫苗的一部分。 我们的目标是检验gd T细胞在人类中控制牛痘病毒感染的机制。 是病毒免疫所必需的,并致力于开发新的治疗方法和改善 结合直接刺激gd T细胞的疫苗接种方法。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
TNF-alpha is a positive regulatory factor for human Vgamma2 Vdelta2 T cells.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

C. David Pauza其他文献

C. David Pauza的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('C. David Pauza', 18)}}的其他基金

T-follicular helper cells in Env-immunized macaques
Env 免疫猕猴中的滤泡辅助 T 细胞
  • 批准号:
    8262539
  • 财政年份:
    2012
  • 资助金额:
    $ 17.25万
  • 项目类别:
FcRn-targeted mucosal HIV vaccine
FcRn 靶向粘膜 HIV 疫苗
  • 批准号:
    8513912
  • 财政年份:
    2012
  • 资助金额:
    $ 17.25万
  • 项目类别:
Synthetic Variable Domain Glycopeptides for Neutralizing Epitope Characterization
用于中和表位表征的合成可变结构域糖肽
  • 批准号:
    8505372
  • 财政年份:
    2012
  • 资助金额:
    $ 17.25万
  • 项目类别:
FcRn-targeted mucosal HIV vaccine
FcRn 靶向粘膜 HIV 疫苗
  • 批准号:
    8685882
  • 财政年份:
    2012
  • 资助金额:
    $ 17.25万
  • 项目类别:
FcRn-targeted mucosal HIV vaccine
FcRn 靶向粘膜 HIV 疫苗
  • 批准号:
    8409840
  • 财政年份:
    2012
  • 资助金额:
    $ 17.25万
  • 项目类别:
T-follicular helper cells in Env-immunized macaques
Env 免疫猕猴中的滤泡辅助 T 细胞
  • 批准号:
    8515924
  • 财政年份:
    2012
  • 资助金额:
    $ 17.25万
  • 项目类别:
Mechanisms for depleting tumor immunity in AIDS
艾滋病中肿瘤免疫耗竭的机制
  • 批准号:
    7759088
  • 财政年份:
    2009
  • 资助金额:
    $ 17.25万
  • 项目类别:
Mechanisms for depleting tumor immunity in AIDS
艾滋病中肿瘤免疫耗竭的机制
  • 批准号:
    8138115
  • 财政年份:
    2009
  • 资助金额:
    $ 17.25万
  • 项目类别:
Mechanisms for depleting tumor immunity in AIDS
艾滋病中肿瘤免疫耗竭的机制
  • 批准号:
    8063017
  • 财政年份:
    2009
  • 资助金额:
    $ 17.25万
  • 项目类别:
Mechanisms for depleting tumor immunity in AIDS
艾滋病中肿瘤免疫耗竭的机制
  • 批准号:
    8254371
  • 财政年份:
    2009
  • 资助金额:
    $ 17.25万
  • 项目类别:

相似海外基金

Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的三信号人工抗原呈递细胞
  • 批准号:
    10751133
  • 财政年份:
    2023
  • 资助金额:
    $ 17.25万
  • 项目类别:
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的微流控精密工程人工抗原呈递细胞
  • 批准号:
    10696138
  • 财政年份:
    2022
  • 资助金额:
    $ 17.25万
  • 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
  • 批准号:
    10663066
  • 财政年份:
    2022
  • 资助金额:
    $ 17.25万
  • 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
  • 批准号:
    10537159
  • 财政年份:
    2022
  • 资助金额:
    $ 17.25万
  • 项目类别:
Analysis of the function of antigen-presenting cells present in the stroma of colorectal cancer and the intracellular microbiome
结直肠癌基质中抗原呈递细胞和细胞内微生物组的功能分析
  • 批准号:
    21K08723
  • 财政年份:
    2021
  • 资助金额:
    $ 17.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
  • 批准号:
    10156950
  • 财政年份:
    2021
  • 资助金额:
    $ 17.25万
  • 项目类别:
The role of CX3CR1+ antigen presenting cells in T cell selection and central tolerance"
CX3CR1抗原呈递细胞在T细胞选择和中枢耐受中的作用"
  • 批准号:
    10631854
  • 财政年份:
    2021
  • 资助金额:
    $ 17.25万
  • 项目类别:
Reprogramming Cancer Cells into Antigen Presenting Cells: Cancer Vaccination with mRNA Enabled by Charge-Altering Releasable Transporters
将癌细胞重编程为抗原呈递细胞:通过改变电荷的可释放转运蛋白实现 mRNA 的癌症疫苗接种
  • 批准号:
    10153927
  • 财政年份:
    2021
  • 资助金额:
    $ 17.25万
  • 项目类别:
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
  • 批准号:
    10331830
  • 财政年份:
    2021
  • 资助金额:
    $ 17.25万
  • 项目类别:
Analysis on detrimental interplay between pathogenic helper T cells, inflammatory antigen-presenting cells and disease-associated microglia in chronic pathogenesis of multiple sclerosis
多发性硬化症慢性发病机制中致病性辅助 T 细胞、炎症抗原呈递细胞和疾病相关小胶质细胞之间的有害相互作用分析
  • 批准号:
    20K16294
  • 财政年份:
    2020
  • 资助金额:
    $ 17.25万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了